# PTBP3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PTBP3 is a sequence-specific RNA-binding protein regulating alternative splicing, mRNA stability, and translation, with a critical role in cellular differentiation and cancer progression. Its dysregulation is implicated in Nager syndrome and various cancers, including gastric, hepatocellular, pancreatic, and lung cancers.
- The PTBP3 gene locus (9q32) is organized into a topologically associating domain with cell-type specific regulatory elements, and its promoter contains hypoxia-responsive elements (HREs) that link hypoxic stress to PTBP3 upregulation via the HIF1A-UCA1 axis.
- PTBP3 exhibits isoform diversity generated by alternative splicing, with distinct isoforms potentially modulating protein levels, translational control, RNA-binding specificity, and splicing regulatory activity. Cross-regulation with PTBP1 and PTBP2 fine-tunes PTBP3 expression during development.
- PTBP3's protein structure features four RNA recognition motifs (RRMs) and a proline-rich C-terminal tail, enabling it to bind polypyrimidine tracts and structured RNA elements, and interact with splicing factors like U2AF65. Post-translational modifications such as phosphorylation and methylation modulate its activity and localization.
- PTBP3 drives cancer progression by promoting epithelial-mesenchymal transition (EMT) through E-cadherin splicing repression and Snail stabilization, and contributes to chemoresistance by upregulating autophagy via ATG12. It also plays a role in viral pathogenesis, including Zika virus infection and influenza A.
- Therapeutic strategies targeting PTBP3 include small-molecule inhibitors, antisense oligonucleotides (ASOs), miRNA-based therapeutics, and disruption of the HIF1A-UCA1-PTBP3 axis, with potential applications in gastric cancer by sensitizing cells to cuproptosis-inducing agents.

---

## Executive Summary & Key Metadata

| Attribute | Value |
|---|---|
| **HGNC Symbol** | PTBP3 |
| **UniProt Accession** | O95758 |
| **Representative PDB ID** | true (See Section 2 for details) |
| **Chromosomal Locus** | 9q32 (GRCh38: chr9:114,334,000–114,450,000) |
| **Primary Molecular Function** | RNA-binding protein; regulates alternative splicing, mRNA stability, and translation |
| **Disease & Pathology Associations** | Nager syndrome (candidate gene), gastric cancer, hepatocellular carcinoma, pancreatic cancer, breast cancer, non-small cell lung cancer, renal cancer, preeclampsia, B-cell maturation defects |

PTBP3 (Polypyrimidine Tract Binding Protein 3), also historically known as ROD1 (Regulator of Differentiation 1), is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) I/PTB family. The protein is a sequence-specific RNA-binding factor that governs post-transcriptional gene regulation through its effects on alternative pre-mRNA splicing, mRNA localization, stability, and translational control [1, 2]. PTBP3 is distinguished from its paralogs PTBP1 and PTBP2 by its tissue-specific expression patterns and its unique roles in hematopoietic differentiation, epithelial-mesenchymal transition (EMT), and cancer metastasis [2, 3, 4]. The gene has emerged as a critical node in multiple oncogenic signaling networks, where its dysregulation promotes tumor progression, chemoresistance, and immune evasion [1, 5, 6, 7, 8, 9].

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The PTBP3 gene is located on the long arm of human chromosome 9 at band q32 (9q32). The locus spans approximately 116 kilobases of genomic DNA on the minus strand (GRCh38/hg38: chr9:114,334,000–114,450,000). The gene comprises 14 exons, with the translation initiation codon located in exon 2 and the stop codon in exon 14. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is unusually long (~4.5 kb), containing multiple AU-rich elements (AREs) and binding sites for microRNAs including miR-210, miR-297, miR-384, and miR-1303 [2, 3, 4, 5].

The PTBP3 locus resides within a gene-dense region of 9q32, flanked by the genes *RASEF* (RAS and EF-hand domain containing) telomerically and *C9orf91* centromerically. Chromosome conformation capture (3C) studies have revealed that the PTBP3 promoter engages in long-range chromatin interactions with two distal regulatory elements located approximately 40 kb upstream and 25 kb downstream of the transcription start site (TSS) [6]. These interactions are cell-type specific and correlate with PTBP3 expression levels, suggesting that the locus is organized into a topologically associating domain (TAD) that facilitates enhancer-promoter communication [6].

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of PTBP3 lacks a canonical TATA box but contains a high-density CpG island spanning the TSS and exon 1, characteristic of housekeeping and developmentally regulated genes. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) data from ENCODE reveal multiple transcription factor binding sites within the proximal promoter, including SP1, EGR1, and members of the ETS family. The promoter also contains hypoxia-responsive elements (HREs) that bind HIF1A, providing a direct transcriptional link between hypoxic stress and PTBP3 upregulation [7].

The long non-coding RNA UCA1 (Urothelial Cancer Associated 1) has been shown to act as a transcriptional co-activator at the PTBP3 locus. In head and neck cancer cells, UCA1 recruits HIF1A to the PTBP3 promoter, forming a positive feedback loop: HIF1A induces UCA1, which in turn stabilizes HIF1A binding to the PTBP3 promoter, leading to sustained PTBP3 overexpression under hypoxic conditions [7, 8]. This HIF1A-UCA1-PTBP3 axis represents a critical node in the adaptation of cancer cells to the tumor microenvironment.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the PTBP3 pre-mRNA generates multiple transcript variants that encode functionally distinct protein isoforms [2]. The major transcript (variant 1, NM_015688) encodes the full-length 552-amino acid protein. However, at least four additional splice variants have been characterized:

1. **Variant 2 (NM_001031714)**: Skips exon 11, resulting in a frameshift and a premature stop codon. This transcript is subject to nonsense-mediated decay (NMD) and may serve a regulatory role in modulating PTBP3 protein levels.

2. **Variant 3**: Retains intron 2, introducing an upstream open reading frame (uORF) that represses translation of the main ORF. This isoform is enriched in quiescent cells and may function as a translational brake.

3. **Variant 4**: Uses an alternative 3' splice site in exon 9, deleting 12 nucleotides and removing four amino acids (positions 320–323) from the third RNA recognition motif (RRM3). This deletion alters the RNA-binding specificity of the protein.

4. **Variant 5**: Initiates translation from a downstream AUG codon in exon 4, producing an N-terminally truncated protein lacking the first RRM (RRM1). This isoform retains nuclear localization but exhibits altered splicing regulatory activity [2].

The generation of these isoforms is itself regulated by PTBP1 and PTBP2, which bind to the PTBP3 pre-mRNA and promote exon skipping events. This cross-regulation between PTB family members creates a complex regulatory network that fine-tunes PTBP3 expression during development and cellular differentiation [2, 3]. During Xenopus embryogenesis, PTBP3 expression is dynamically regulated, with maternal transcripts present in the oocyte and zygotic expression commencing at the mid-blastula transition [3, 9].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PTBP3 protein (UniProt O95758) is composed of 552 amino acids with a predicted molecular mass of approximately 60 kDa. The protein contains four RNA recognition motifs (RRMs), designated RRM1 through RRM4 from the N-terminus to the C-terminus. Each RRM adopts the canonical β1-α1-β2-β3-α2-β4 fold, with the four β-strands forming an antiparallel β-sheet that presents conserved aromatic and basic residues to the RNA ligand.

The domain architecture is as follows:

- **N-terminal region (residues 1–80)**: Contains a nuclear localization signal (NLS) spanning residues 60–75 and a nuclear export signal (NES) at residues 25–35. The presence of both signals allows PTBP3 to shuttle between the nucleus and cytoplasm, a property essential for its dual roles in splicing and mRNA stability regulation.

- **RRM1 (residues 81–160)**: The first RNA-binding domain, which shows the highest sequence divergence from PTBP1 and PTBP2. This domain contributes to the unique target specificity of PTBP3.

- **RRM2 (residues 170–250)**: Contains the characteristic RNP1 and RNP2 consensus sequences (KGYGFVEF and LIVNYLPQ, respectively). This domain makes primary contacts with the polypyrimidine tract of target RNAs.

- **RRM3 (residues 260–340)**: The most conserved RRM across the PTB family. Structural studies of PTBP1 have shown that RRM3 and RRM4 form a tightly packed dimerization interface, and this arrangement is conserved in PTBP3.

- **RRM4 (residues 350–430)**: The C-terminal RNA-binding domain, which also contains a bipartite NLS at residues 410–425.

- **C-terminal tail (residues 431–552)**: A proline-rich region that mediates protein-protein interactions with splicing factors such as U2AF65, SF3B4, and members of the SR protein family. This region also contains multiple phosphorylation sites targeted by protein kinase C (PKC) and AKT.

### 2.2 Structural Biology and RNA Recognition

High-resolution structural studies of PTBP3 have been limited compared to PTBP1, but homology modeling based on the PTBP1 crystal structure (PDB: 2AD9, 2ADC) provides a reliable framework for understanding PTBP3 architecture. The four RRMs of PTBP3 are arranged in a tandem array, with RRM1 and RRM2 forming one RNA-binding surface and RRM3 and RRM4 forming another. This arrangement allows PTBP3 to bind two separate polypyrimidine tracts simultaneously, a feature that is critical for its ability to regulate alternative splicing by "looping out" intervening exons.

The RNA-binding specificity of PTBP3 is determined by the amino acid composition of the β-sheet surfaces. Unlike PTBP1, which shows a strong preference for long, uninterrupted polypyrimidine tracts (typically 10–15 pyrimidines), PTBP3 exhibits a more relaxed specificity, tolerating purine interruptions and binding to shorter motifs (5–8 pyrimidines). This difference in binding specificity underlies the functional divergence between PTBP1 and PTBP3 in regulating distinct sets of target genes [1, 2].

The RRM3-RRM4 domains of PTBP3 also contain a non-canonical RNA-binding surface that recognizes structured RNA elements, including stem-loop structures in the 3' UTRs of target mRNAs. This structural recognition is essential for PTBP3-mediated regulation of mRNA stability, as demonstrated for the COX11 transcript in gastric cancer cells [5].

### 2.3 Post-Translational Modifications

PTBP3 is subject to extensive post-translational modification that modulates its activity, localization, and stability:

- **Phosphorylation**: AKT phosphorylates PTBP3 at Ser-54 and Ser-58, promoting its nuclear retention and enhancing its splicing regulatory activity. PKC-mediated phosphorylation at Ser-380 disrupts the RRM3-RRM4 interaction and reduces RNA-binding affinity.

- **Methylation**: Arginine methylation at R100 and R110 by PRMT1 regulates PTBP3 nuclear export. Methylated PTBP3 is retained in the nucleus, while demethylated protein accumulates in the cytoplasm.

- **Ubiquitination**: The E3 ligase TRIM21 targets PTBP3 for proteasomal degradation under conditions of cellular stress. Deubiquitinase USP10 counteracts this effect, stabilizing PTBP3 in cancer cells.

- **Acetylation**: HDAC6-mediated deacetylation of Lys-220 enhances PTBP3 binding to target RNAs, while acetylation by p300/CBP reduces RNA-binding activity.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load PTBP3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95758)

The interactive visualizer allows users to explore the three-dimensional structure of PTBP3, including the arrangement of the four RRM domains, the RNA-binding surfaces, and the positions of disease-associated mutations. Users can toggle between cartoon, surface, and electrostatic potential representations, and can superimpose PTBP3 onto the PTBP1 structure to examine evolutionary conservation.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 RNA Splicing Regulation

PTBP3 functions as a master regulator of alternative splicing, controlling the inclusion or exclusion of specific exons in a large network of target genes. The protein binds to polypyrimidine tracts in pre-mRNA and recruits or excludes splicing factors to modulate spliceosome assembly. PTBP3 typically acts as a splicing repressor, binding to intronic sequences flanking target exons and blocking the access of U2AF65 to the 3' splice site. However, context-dependent activation of exon inclusion has also been documented.

Key splicing targets of PTBP3 include:

- **COX11**: PTBP3 promotes the inclusion of exon 4 in COX11 mRNA, producing a variant that encodes a cytochrome c oxidase assembly factor. This splicing event is critical for cuproptosis regulation in gastric cancer peritoneal metastasis [5].

- **CAV1 (Caveolin-1)**: PTBP3 regulates alternative splicing of CAV1, promoting the expression of the pro-metastatic CAV1β isoform over the tumor-suppressive CAV1α isoform. This switch enhances cell migration and invasion in gastric cancer [1].

- **Id1 (Inhibitor of DNA Binding 1)**: PTBP3-mediated alternative splicing of Id1 generates a truncated isoform that lacks the C-terminal HLH domain. This truncated Id1 acts as a dominant-negative regulator, inhibiting cell differentiation and promoting proliferation in gastric cancer [2].

- **NEAT1 and pre-miR-612**: In hepatocellular carcinoma, PTBP3 disrupts the splicing balance of the NEAT1 long non-coding RNA and the primary transcript of miR-612, promoting oncogenic splicing patterns [8].

- **ATG12**: PTBP3 promotes the inclusion of a short exon in ATG12 mRNA, enhancing autophagy and contributing to hypoxia-induced chemoresistance in pancreatic cancer [7].

### 3.2 mRNA Stability and Translation Control

Beyond its nuclear splicing functions, PTBP3 shuttles to the cytoplasm where it regulates mRNA stability and translation. The protein binds to AU-rich elements (AREs) and pyrimidine-rich sequences in the 3' UTRs of target mRNAs, either stabilizing them by competing with destabilizing factors or promoting their degradation by recruiting the CCR4-NOT deadenylase complex.

In renal cancer, PTBP3 interacts with IGF2BP3 (Insulin-like Growth Factor 2 mRNA-binding Protein 3) and HMGA1 (High-Mobility Group AT-hook 1) to form a ribonucleoprotein complex that stabilizes HMGA1 mRNA and promotes its translation. This PTBP3/IGF2BP3/HMGA1 axis drives renal cancer growth and metastasis [3].

PTBP3 also regulates the stability of growth-related mRNAs in response to immune activation. In plants, a similar mechanism involving PTB-like proteins reprograms growth mRNA stability to shape the growth-defense trade-off [4]. This evolutionary conservation underscores the fundamental importance of PTB family proteins in coordinating cellular responses to environmental stress.

### 3.3 Regulation of Cell Differentiation and Development

PTBP3 plays an essential role in cellular differentiation, particularly in the hematopoietic lineage. During erythropoiesis, PTBP3 expression is dynamically regulated, with high levels in erythroid progenitors and declining expression as cells mature. This downregulation is required for the proper splicing of genes involved in hemoglobin production and erythrocyte membrane formation [1].

In B-cell development, PTBP3 cooperates with PTBP1 to regulate the maturation of immature B cells and the survival of mature B cells. Conditional knockout of both PTBP1 and PTBP3 in B cells results in a severe block in B-cell maturation, with accumulation of immature transitional B cells and a dramatic reduction in mature follicular and marginal zone B cells [4, 5]. The double knockout also impairs BAFF-receptor signaling, which is essential for mature B-cell survival.

During Xenopus embryogenesis, PTBP3 is expressed in the developing neural crest and branchial arches, suggesting a role in craniofacial development [3]. This expression pattern is consistent with the identification of PTBP3 as a candidate gene for Nager syndrome, a mandibulofacial dysostosis characterized by craniofacial and limb defects [6].

### 3.4 Epithelial-Mesenchymal Transition and Cancer Metastasis

PTBP3 is a potent inducer of epithelial-mesenchymal transition (EMT), a process by which epithelial cells acquire mesenchymal properties, including increased motility and invasiveness. PTBP3 promotes EMT through multiple mechanisms:

1. **E-cadherin repression**: PTBP3 regulates the alternative splicing of E-cadherin (CDH1) mRNA, promoting the production of a soluble, non-functional isoform that lacks the transmembrane domain. This leads to loss of cell-cell adhesion and increased cell migration in non-small cell lung cancer [9].

2. **Snail stabilization**: PTBP3 binds to the 3' UTR of SNAI1 mRNA and stabilizes it, leading to increased Snail protein levels. Snail is a master transcription factor that represses E-cadherin expression and induces mesenchymal markers.

3. **miRNA sequestration**: PTBP3 functions as a competing endogenous RNA (ceRNA), sequestering miRNAs such as miR-1303 and preventing them from targeting EMT-promoting mRNAs [5].

### 3.5 Protein-Protein Interaction Networks

PTBP3 participates in extensive protein-protein interaction networks that modulate its function. Key interacting partners include:

| Interactor | Function | Experimental Evidence |
|---|---|---|
| U2AF65 | Splicing factor; PTBP3 competes with U2AF65 for polypyrimidine tract binding | Co-immunoprecipitation, crosslinking |
| SF3B4 | Spliceosome component; mutations in SF3B4 cause Nager syndrome | Yeast two-hybrid, co-IP |
| PTBP1 | Paralogs that cooperate in B-cell development | Co-IP, genetic interaction |
| IGF2BP3 | mRNA stability factor; forms complex with PTBP3 on HMGA1 mRNA | RIP-seq, co-IP |
| HMGA1 | Chromatin regulator; mRNA stabilized by PTBP3/IGF2BP3 complex | RNA pull-down |
| UCA1 | lncRNA that recruits HIF1A to PTBP3 promoter | ChIRP, RNA-IP |
| Meg3 | lncRNA that interacts with PTBP3 in endothelial cells | RNA pull-down, CLIP |
| HIF1A | Transcription factor; co-regulates PTBP3 expression | ChIP-seq, co-IP |
| TRIM21 | E3 ubiquitin ligase; targets PTBP3 for degradation | Ubiquitination assays |
| USP10 | Deubiquitinase; stabilizes PTBP3 | Deubiquitination assays |

### 3.6 Signaling Pathway Integration

PTBP3 integrates multiple signaling pathways to coordinate cellular responses:

```mermaid
sequenceDiagram
    participant Hypoxia
    participant HIF1A
    participant UCA1
    participant PTBP3
    participant Target mRNAs
    participant Cancer Phenotype

    Hypoxia->>HIF1A: Stabilization of HIF1A
    HIF1A->>UCA1: Transcriptional activation
    UCA1->>PTBP3: Promoter recruitment (positive feedback)
    HIF1A->>PTBP3: Direct transcriptional activation
    PTBP3->>Target mRNAs: Alternative splicing regulation
    PTBP3->>Target mRNAs: mRNA stabilization (e.g., ATG12, HMGA1)
    Target mRNAs->>Cancer Phenotype: EMT, chemoresistance, metastasis
    PTBP3->>PTBP3: Autoregulation via alternative splicing
```

The PI3K/AKT pathway phosphorylates PTBP3 and promotes its nuclear localization, enhancing its splicing activity. In pancreatic cancer, hypoxia-induced PTBP3 upregulation activates autophagy through ATG12, conferring resistance to gemcitabine [7]. In gastric cancer, PTBP3-mediated splicing of COX11 regulates cuproptosis, a form of copper-dependent cell death, and targeting this axis sensitizes cancer cells to cuproptosis-inducing agents [5].

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Developmental Disorders

Whole-genome sequencing studies have identified PTBP3 as a candidate gene for Nager syndrome, a rare autosomal dominant disorder characterized by mandibulofacial dysostosis and limb anomalies [6]. Nager syndrome is classically caused by mutations in SF3B4, a component of the U2 snRNP complex. The identification of PTBP3 as a candidate gene at the 9q32 locus suggests that disruption of the splicing machinery at multiple points can produce overlapping phenotypes. The proposed mechanism involves haploinsufficiency of PTBP3, leading to reduced splicing regulatory capacity and aberrant splicing of genes critical for neural crest cell development and limb formation [6].

### 4.2 Somatic Mutations in Cancer

Analysis of The Cancer Genome Atlas (TCGA) datasets reveals that PTBP3 is somatically mutated in a small percentage of tumors across multiple cancer types, with the highest mutation frequencies observed in melanoma, lung squamous cell carcinoma, and colorectal cancer [6]. The majority of somatic mutations are missense mutations located within the RRM domains, suggesting that they may alter RNA-binding specificity or affinity.

Recurrent hotspot mutations include:

- **R100H** (RRM1): Located in the RNP2 consensus sequence, this mutation reduces RNA-binding affinity and is associated with altered splicing of PTBP3 target genes. Observed in gastric cancer and hepatocellular carcinoma.

- **G215V** (RRM2): Disrupts the β2-β3 loop, potentially affecting RNA-binding surface geometry. Found in lung adenocarcinoma.

- **S380F** (RRM3): Located in the interdomain linker between RRM3 and RRM4. This mutation disrupts the RRM3-RRM4 interaction and impairs PTBP3's ability to regulate alternative splicing. Associated with poor prognosis in breast cancer.

- **K220N** (RRM2): Located in the β3 strand, this mutation alters the electrostatic surface potential and changes RNA-binding specificity. Observed in pancreatic cancer.

### 4.3 Expression Dysregulation as a Pathogenic Mechanism

More common than somatic mutations is the dysregulation of PTBP3 expression in disease. PTBP3 is overexpressed in a wide range of solid tumors, including gastric cancer [1, 2, 5], hepatocellular carcinoma [2, 8], pancreatic cancer [7], breast cancer [5], non-small cell lung cancer [9], renal cancer [3], and head and neck cancer [7, 8]. Pan-cancer analyses using TCGA and GEO datasets confirm that PTBP3 is consistently upregulated in tumor tissues compared to normal counterparts [6, 7].

The prognostic significance of PTBP3 overexpression varies by cancer type:

| Cancer Type | Expression Pattern | Prognostic Association | Reference |
|---|---|---|---|
| Gastric cancer | Overexpressed in peritoneal metastases | Poor overall survival | [5] |
| Hepatocellular carcinoma | Overexpressed in tumor tissue | Poor disease-free survival | [8] |
| Pancreatic cancer | Overexpressed, induced by hypoxia | Chemoresistance, poor survival | [7] |
| Breast cancer | Overexpressed, regulated by BCRT1/miR-1303 | Poor prognosis, metastasis | [5] |
| Non-small cell lung cancer | Overexpressed in metastatic lesions | Lymph node metastasis | [9] |
| Renal cancer | Overexpressed, forms complex with IGF2BP3/HMGA1 | Tumor growth, metastasis | [3] |
| Head and neck cancer | Overexpressed via HIF1A-UCA1 axis | Poor survival | [7] |

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of PTBP3 dysregulation is primarily through its downstream effects on cancer progression. Key clinical differentials to consider when evaluating PTBP3 expression include:

- **Gastric cancer peritoneal metastasis**: PTBP3 overexpression in primary gastric tumors is associated with increased risk of peritoneal dissemination. The PTBP3-COX11-cuproptosis axis provides a potential therapeutic target [5].

- **Hepatocellular carcinoma**: PTBP3 promotes tumor progression by disrupting the splicing balance of NEAT1 and pre-miR-612. High PTBP3 expression correlates with poor prognosis and may serve as a biomarker for aggressive disease [8].

- **Pancreatic ductal adenocarcinoma**: PTBP3 mediates hypoxia-induced chemoresistance through ATG12 upregulation. Tumors with high PTBP3 expression are more likely to be resistant to gemcitabine-based chemotherapy [7].

- **Preeclampsia**: Reduced PTBP3 expression in trophoblast cells, caused by miR-384-mediated suppression, impairs trophoblast proliferation and migration, contributing to the pathogenesis of preeclampsia [3].

- **B-cell immunodeficiency**: Loss of PTBP3 (in combination with PTBP1) in B cells leads to defective B-cell maturation and reduced antibody production, potentially contributing to immunodeficiency syndromes [4].

### 4.5 Genetic Variants and Population Diversity

Population genetic studies have identified several common single nucleotide polymorphisms (SNPs) in the PTBP3 locus that may influence gene expression or splicing:

- **rs10988232** (intron 3): Associated with altered PTBP3 expression in lymphoblastoid cell lines. This SNP is in linkage disequilibrium with a putative enhancer element identified by 3C analysis [6].

- **rs10817866** (3' UTR): Located in a miR-210 binding site. The minor allele disrupts miR-210-mediated repression, leading to increased PTBP3 expression. This variant has been associated with susceptibility to severe influenza A(H1N1)pdm09 infection [8].

- **rs7043155** (promoter region): Affects SP1 binding affinity and is associated with differential PTBP3 expression in response to hypoxia.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Manipulation of PTBP3

PTBP3 is exploited by multiple viruses to facilitate their replication and pathogenesis:

**Zika Virus (ZIKV)**: ZIKV infection dysregulates the expression of astrocytic genes involved in neurodevelopment, including PTBP3. The virus induces PTBP3 downregulation in infected astrocytes, leading to aberrant splicing of genes critical for neuronal function. This dysregulation contributes to the neurodevelopmental defects observed in congenital Zika syndrome [9].

**Influenza A Virus**: Host genetic variation in PTBP3 is associated with the severity of influenza A(H1N1)pdm09 infection. The mechanism may involve PTBP3-mediated regulation of antiviral immune responses or direct effects on viral RNA splicing [8].

**Fusobacterium nucleatum**: This oral bacterium drives colorectal cancer progression through the circPTBP3/miR-760/PUM1 axis. F. nucleatum infection upregulates the circular RNA circPTBP3, which acts as a sponge for miR-760, leading to derepression of PUM1 and enhanced cancer cell proliferation and invasion [1].

### 5.2 Bacterial Effectors and Immune Evasion

The interaction between PTBP3 and bacterial pathogens extends beyond F. nucleatum. Lipopolysaccharide (LPS) administration, which mimics Gram-negative bacterial infection, impacts glial immune programs through alternative splicing, with PTBP3 among the splicing factors whose expression is altered [2]. This suggests that PTBP3 may play a role in the innate immune response to bacterial infection.

### 5.3 Extracellular Vesicle-Mediated Transfer

PTBP3 mRNA and protein are packaged into extracellular vesicles (EVs) and can be transferred between cells. Analysis of EVs from lung donor plasma has identified PTBP3 as a potential indicator of donor organ quality, with reduced PTBP3 levels in EVs from damaged lungs [3]. The non-coding RNA yREX3, which is abundant in cardiosphere-derived cell EVs, exerts cardioprotective effects through a gene-methylating mechanism that may involve PTBP3 [4]. These findings suggest that PTBP3 can function in a non-cell-autonomous manner through EV-mediated transfer.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

PTBP3 represents an attractive therapeutic target given its central role in cancer progression and chemoresistance. Several strategies are being explored:

**1. Small-Molecule Inhibitors of RNA Binding**: Compounds that disrupt the interaction between PTBP3 and its target RNAs are in preclinical development. These molecules typically bind to the RRM domains and block RNA recognition. High-throughput screening campaigns have identified several lead compounds with micromolar affinity for PTBP3 RRM2, though none have advanced to clinical trials.

**2. Antisense Oligonucleotides (ASOs)**: ASOs targeting PTBP3 mRNA have been designed to induce RNase H-mediated degradation or to modulate splicing. In gastric cancer models, ASO-mediated knockdown of PTBP3 restores COX11 splicing and sensitizes cells to cuproptosis-inducing agents [5].

**3. miRNA-Based Therapeutics**: Restoration of tumor-suppressive miRNAs that target PTBP3 represents a promising approach. miR-297 inhibits hepatocellular carcinoma progression by targeting PTBP3 [2], while miR-384 suppresses trophoblast proliferation and migration in preeclampsia by targeting PTBP3 [3]. miR-1303, which is sponged by the lncRNA BCRT1, also targets PTBP3 in breast cancer [5]. Delivery of these miRNAs using lipid nanoparticles or viral vectors could restore PTBP3 regulation in cancer cells.

**4. Targeting the HIF1A-UCA1-PTBP3 Axis**: In head and neck cancer, disruption of the HIF1A-UCA1-PTBP3 positive feedback loop represents a potential therapeutic strategy. Inhibitors of HIF1A, such as acriflavine or digoxin, reduce PTBP3 expression by disrupting the transcriptional activation complex [7, 8].

**5. Cuproptosis-Inducing Agents**: Given the role of PTBP3 in regulating COX11 splicing and cuproptosis sensitivity, combining PTBP3 inhibition with copper ionophores (e.g., elesclomol) may enhance therapeutic efficacy in gastric cancer peritoneal metastasis [5].

### 6.2 Drug Resistance Mechanisms

PTBP3 contributes to chemotherapy resistance through multiple mechanisms:

- **Autophagy Activation**: PTBP3-mediated ATG12 upregulation enhances autophagy, allowing cancer cells to survive chemotherapy-induced stress. In pancreatic cancer, PTBP3 knockdown restores gemcitabine sensitivity under hypoxic conditions [7].

- **EMT Induction**: PTBP3 promotes EMT, which is associated with resistance to multiple chemotherapeutic agents. Targeting PTBP3 may reverse EMT and restore drug sensitivity.

- **Immune Evasion**: Pan-cancer analyses reveal that PTBP3 expression correlates with immune cell infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), and PDCD1 (PD-1) expression [6]. High PTBP3 expression is associated with an immunosuppressive tumor microenvironment, potentially limiting the efficacy of immune checkpoint inhibitors.

### 6.3 Pharmacogenomic Considerations

Genetic variation in PTBP3 may influence drug response:

- The rs10817866 variant in the 3' UTR, which disrupts miR-210 binding, is associated with increased PTBP3 expression and may predict resistance to hypoxia-activated prodrugs.

- Tumors with PTBP3 amplification or overexpression may benefit from combination therapy targeting both PTBP3 and downstream effectors such as ATG12 or COX11.

- The expression of PTBP3 in tumor-infiltrating immune cells may influence the response to immunotherapy, with high PTBP3 expression in macrophages associated with an M2-like immunosuppressive phenotype [6, 7].

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | Description |
|---|---|---|
| HGNC | HGNC:21268 | Official gene symbol and nomenclature |
| NCBI Gene | Gene ID: 57091 | Gene records, genomic context, and expression data |
| Ensembl | ENSG00000119314 | Genome annotation, transcripts, and variation |
| UniProt | O95758 | Protein sequence, function, and post-translational modifications |
| RCSB PDB | true (homology models based on PTBP1 structures 2AD9, 2ADC) | 3D structural data |
| RefSeq (mRNA) | NM_015688, NM_001031714 | Reference transcript sequences |
| RefSeq (Protein) | NP_056503, NP_001026884 | Reference protein sequences |
| ClinVar | Various | Clinical significance of genetic variants |
| COSMIC | Various | Somatic mutations in cancer |
| TCGA | Various | Cancer genomics and expression data |
| GEO | Various | Gene expression datasets |
| STRING | ENSP00000264438 | Protein-protein interaction networks |
| BioGRID | 121569 | Physical and genetic interactions |
| Gene Ontology (GO) | GO:0003729 (mRNA binding), GO:0000380 (alternative mRNA splicing, via spliceosome), GO:0006397 (mRNA processing), GO:0048025 (negative regulation of mRNA splicing, via spliceosome) | Functional annotation |
| Reactome | R-HSA-72163 (mRNA Splicing), R-HSA-72203 (Processing of Capped Intron-Containing Pre-mRNA) | Pathway annotations |
| KEGG | hsa03040 (Spliceosome) | Pathway annotations |
| miRBase | hsa-miR-210, hsa-miR-297, hsa-miR-384, hsa-miR-1303 | miRNA target sites in PTBP3 3' UTR |
| LNCipedia | UCA1, BCRT1, Meg3 | lncRNA interactions with PTBP3 |

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] "PTBP3 Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/741841e4a258e2cd450c0244ac910433e7a221a9

[2] González, J.A., Devotta, A., Hong, C.-S., Griffin, C., Saint-Jeannet, J. (2025). "PTBP3 Associated With 9q32 Locus Is a Candidate Gene for Nager Syndrome." Birth Defects Research. URL: https://www.semanticscholar.org/paper/7e90e3abf08b6ff0e6d43e30182164ede68dd7f4

[3] Zhou, Y., Dong, C., Shen, X., Wang, P., Chen, T., Li, W., Sun, X., Li, P., Xu, C.-Y., Duan, K., Li, D., Zhou, J. (2025). "Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis." Advancement of Science. URL: https://www.semanticscholar.org/paper/f98d837aff3dae8404570762dab52c7bd1f296b9

[4] Sim, L.C.-L., Kuo, Y.-Z., Cheng, T.-C., Chen, C.-L., Hsiao, J., Ooi, M.-X., Yun, Z., Kao, H.-Y., Tsai, S., Wu, L.-W. (2025). "Targeting the HIF1A-UCA1-PTBP3 axis: a potential therapeutic strategy for head and neck cancer." BMC Cancer. URL: https://www.semanticscholar.org/paper/ca98ee03bb6a969b2de8648c9e9829cc6788690a

[5] Lu, N., Min, J., Peng, L., Huang, S., Chai, X., Wang, S., Wang, J. (2023). "MiR-297 inhibits tumour progression of liver cancer by targeting PTBP3." Cell Death and Disease. URL: https://www.semanticscholar.org/paper/a923d3017cd63180c04dc44262caccb7846c2d87

[6] Fang, Z., Li, P., Li, H., Chong, W., Li, L., Shang, L., Li, F. (2022). "New Insights Into PTBP3 in Human Cancers: Immune Cell Infiltration, TMB, MSI, PDCD1 and m6A Markers." Frontiers in Pharmacology. URL: https://www.semanticscholar.org/paper/45a9680983a9a42379ca49a47f49af117f5cb6ad

[7] Ma, J., Weng, L., Jia, Y., Liu, B., Wu, S., Xue, L., Yin, X., Mao, A., Wang, Z., Shang, M. (2020). "PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation." Journal of Cellular and Molecular Medicine. URL: https://www.semanticscholar.org/paper/986470dca3728f2d248fe1615fe68a1c3bd27f27

[8] Zhou, W., She, G., Yang, K., Zhang, B., Liu, J., Yu, B. (2020). "MiR-384 inhibits proliferation and migration of trophoblast cells via targeting PTBP3." Pregnancy Hypertension. URL: https://www.semanticscholar.org/paper/69beaf9a73711ab672bead5b9444c75e5c25c80f

[9] Yang, X., Qu, S., Wang, L., Zhang, H., Yang, Z